The Hyderabad-based Biological E and US-based Ohio State Innovation Foundation (OSIF) have signed an exclusive agreement for sharing the necessary technology to develop a COVID-19 vaccine in the coming days.
As part of the agreement, the OSIF has licensed novel live attenuation measles virus vectored vaccine candidate against SARS-Cov-2, which were developed by the Ohio State University College of Veterinary Medicine (OSUCVM).
In continuation to this, the Hyderabad based vaccine maker BE will be responsible for the evaluation and further development, including commercialization of the vaccine. “Biological E is a global vaccine maker and we are excited to further evaluate and develop a new vaccine through the platform of OSUCVM,” informed Mahima Datla, managing director and CEO of BE.
According to Dr. Patrick Green, Associate Dean for Research and Graduate Studies, Ohio State University College of Veterinary Medicine, the translation process of the research work done by the university to that of to a global vaccine manufacturing company like BE is a very critical process and an important step, because now the scientists at the BE will be analyzing and evaluate the research process and practically develop a new vaccine that is safe, effective and long lasting.
It is learnt that the Ohio college research team chose the approach to utilize the SARS Covi-2 spike protein as a target protein for SARS-Cov-2 vaccine candidate, which will generate a series of attenuated recombinant measles viruses (rMeVs) expressing SARS-Cov-2 antigens.
Later a World Health Organization approved cell line for vaccine production process is followed, where in all resultant rMeVs, which are the basis for the vaccine candidates, will grow to high virus titer in Vero cells. The Viro cells were also shown to express the recombinant S antigens, a critical step in developing a SARS-Cov-2 vaccine.
As already the rMeVs based SARS-Cov-2 vaccine candidates have already proceed through proof-of concept trials in multiple animal bodies, it has demonstrated successful production of SARS-Cov-2 antibodies.
Source : 1